Ipsen: collaboration agreement with Skyhawk

(CercleFinance.com) - Ipsen announces the signature of an exclusive global collaboration agreement with Skyhawk Therapeutics, aimed at the discovery and development of novel small molecules capable of modulating RNA splicing in rare neurological diseases.


This agreement gives Ipsen the option to acquire an exclusive license for the worldwide development rights to validated drug candidates. Once the development candidate has been selected, it will be responsible for all activities relating to it.

Skyhawk is eligible for an upfront payment for the research collaboration, payments conditional on option exercise and regulatory and commercial milestones, totaling up to $1.8bn, as well as potential royalties.


Copyright (c) 2024 CercleFinance.com. All rights reserved.